As China Biotechs Mull Global Approaches, Commercial Insurance Holds Key To Domestic Success

 
• By Xu Hu

Low prices and intense competition for innovative drugs at home continue to drive Chinese biotechs' globalization. Broader domestic commercial health insurance might provide the key to change.

Sailing race
Chinese biotechs continue navigating into global markets, but what's needed for the smoothest sailing? (Shutterstock)
Xu Hu

Read more by Xu Hu

Xu is a senior reporter and covers aspects on policy and regulations in China pharma industry within the APAC Pharma news team.

More from Focus On Asia

More from Business